2021
Perioperative thrombocytopenia
Lombard FW, Popescu WM, Oprea AD, Kertai MD. Perioperative thrombocytopenia. Current Opinion In Anaesthesiology 2021, 34: 335-344. PMID: 33935182, DOI: 10.1097/aco.0000000000000999.Peer-Reviewed Original ResearchConceptsPlatelet countThrombopoietin receptor agonistsRisk of bleedingProphylactic platelet transfusionsProthrombin complex concentrateRecombinant factor VIIGood quality evidenceThreshold platelet countIntravenous immunoglobulinPreoperative thrombocytopeniaAsymptomatic patientsPerioperative strategiesPerioperative managementSevere bleedingAntifibrinolytic agentsPlatelet transfusionsComplex concentrateQuality evidenceFibrinogen levelsReceptor agonistPerioperative thrombocytopeniaPlatelet functionThrombin generationIntraoperative alternativeFactor VIIAge-Dependent Heterogeneity in the Efficacy of Prophylaxis With Enoxaparin Against Catheter-Associated Thrombosis in Critically Ill Children: A Post Hoc Analysis of a Bayesian Phase 2b Randomized Clinical Trial.
Faustino EVS, Raffini LJ, Hanson SJ, Cholette JM, Pinto MG, Li S, Kandil SB, Nellis ME, Shabanova V, Silva CT, Tala JA, McPartland T, Spinella PC. Age-Dependent Heterogeneity in the Efficacy of Prophylaxis With Enoxaparin Against Catheter-Associated Thrombosis in Critically Ill Children: A Post Hoc Analysis of a Bayesian Phase 2b Randomized Clinical Trial. Critical Care Medicine 2021, 49: e369-e380. PMID: 33566465, PMCID: PMC7979442, DOI: 10.1097/ccm.0000000000004848.Peer-Reviewed Original ResearchConceptsCentral venous catheter-associated deep venous thrombosisCatheter-associated deep venous thrombosisCentral venous cathetersEfficacy of prophylaxisDeep venous thrombosisAge-dependent heterogeneityAnti-Xa levelsVenous cathetersVenous thrombosisFactor VIII activityThrombin generationPlatelet countClinical trialsIll childrenPhase 2bVIII activityLow factor VIII activityCatheter-Associated ThrombosisInternational units/mLMinimum platelet countOlder childrenCritically Ill ChildrenEndogenous thrombin potentialHigher platelet countsPost Hoc Analysis
2020
Efficacy of Early Prophylaxis Against Catheter-Associated Thrombosis in Critically Ill Children: A Bayesian Phase 2b Randomized Clinical Trial.
Faustino EVS, Shabanova V, Raffini LJ, Kandil SB, Li S, Pinto MG, Cholette JM, Hanson SJ, Nellis ME, Silva CT, Chima R, Sharathkumar A, Thomas KA, McPartland T, Tala JA, Spinella PC. Efficacy of Early Prophylaxis Against Catheter-Associated Thrombosis in Critically Ill Children: A Bayesian Phase 2b Randomized Clinical Trial. Critical Care Medicine 2020, 49: e235-e246. PMID: 33372745, PMCID: PMC7902342, DOI: 10.1097/ccm.0000000000004784.Peer-Reviewed Original ResearchConceptsCentral venous catheter-associated deep venous thrombosisCatheter-associated deep venous thrombosisDeep venous thrombosisUsual care armCentral venous cathetersVenous thrombosisClinical trialsEnoxaparin armCare armVenous cathetersEarly prophylaxisIll childrenThrombin generationPhase 2bCatheter-Associated ThrombosisInternational units/mLAnti-Xa levelsCritically Ill ChildrenRandomized clinical trialsEndogenous thrombin potentialRelevant bleedingUsual careTrial armsRisk ratioThrombin potentialIn Vitro Evaluation of Thrombin Generation of Eptacog Beta (Factor VIIa, Recombinant) and Emicizumab in Congenital Hemophilia Α Plasma with and without Inhibitors
Pipe S, Recht M, Callaghan M, Sidonio R, Grandoni J, Duretz V, Bonzo D, Plantier J, Evans S, Mitchell I, Hermans C. In Vitro Evaluation of Thrombin Generation of Eptacog Beta (Factor VIIa, Recombinant) and Emicizumab in Congenital Hemophilia Α Plasma with and without Inhibitors. Blood 2020, 136: 41-42. DOI: 10.1182/blood-2020-136430.Peer-Reviewed Original ResearchHemophilia A inhibitorsEndogenous thrombin potentialEntity's Board of DirectorsEptacog betaBleeding eventsHemophilia AThromboembolic eventsPeak thrombinClinical trialsConcentration-dependent increaseThrombin generationControl of bleeding eventsTreatment of bleeding eventsPhase 3 clinical trialsPhase 1b trialVelocity indexInitial dosing regimensIncidence of rebleedingPeak plasma levelsFrequency of bleedingPhase 3 trialCurrent equity holderPhase 4 trialClinically relevant combinationsPlatelet-rich plasmaAcute Kidney Injury in Decompensated Cirrhosis Is Associated With Both Hypo‐coagulable and Hyper‐coagulable Features
Zanetto A, Rinder HM, Campello E, Saggiorato G, Deng Y, Ciarleglio M, Wilson FP, Senzolo M, Gavasso S, Bulato C, Simioni P, Garcia‐Tsao G. Acute Kidney Injury in Decompensated Cirrhosis Is Associated With Both Hypo‐coagulable and Hyper‐coagulable Features. Hepatology 2020, 72: 1327-1340. PMID: 32614088, PMCID: PMC8672302, DOI: 10.1002/hep.31443.Peer-Reviewed Original ResearchConceptsAcute kidney injuryPlasmin-antiplasmin complexDecompensated cirrhosisHemostasis assessmentVon Willebrand factorKidney injuryPlatelet functionThrombin generationPlatelet aggregationSeverity of cirrhosisMedian serum creatinineWillebrand factorLower platelet aggregationAnti-coagulant factorsImpaired platelet functionAKI resolutionHypercoagulable featuresSerum creatinineAspects of hemostasisCirrhosis patientsPlatelet countProspective studyFibrinolytic factorsCirrhosisHyperfibrinolytic state
2019
Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis
Samuelson Bannow B, Recht M, Négrier C, Hermans C, Berntorp E, Eichler H, Mancuso M, Klamroth R, O'Hara J, Santagostino E, Matsushita T, Kessler C. Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis. Blood Reviews 2019, 35: 43-50. PMID: 30922616, DOI: 10.1016/j.blre.2019.03.002.Peer-Reviewed Original ResearchConceptsFactor VIII proteinHemophilia AVon Willebrand factorBleeding eventsHemophilia A.Treatment of bleeding eventsHemophilia A managementMouse models of hemophiliaPrevent bleeding eventsMaintenance of bone healthExpression of receptor activatorIntrinsic pathway of coagulationTreating hemophilia AFollow-up dataStandard of careLongitudinal follow-up dataPathway of coagulationFVIII levelsRegulation of angiogenesisBone turnoverVenous thromboembolismBone healthThrombin generationReceptor activationMouse model
2009
A Randomized Clinical Trial Investigating the Relationship Between Aprotinin and Hypercoagulabilityin Off-Pump Coronary Surgery
Desai P, Kurian D, Thirumavalavan N, Desai S, Ziu P, Grant M, White C, Landis R, Poston R. A Randomized Clinical Trial Investigating the Relationship Between Aprotinin and Hypercoagulabilityin Off-Pump Coronary Surgery. Anesthesia & Analgesia 2009, 109: 1387-1394. PMID: 19843776, PMCID: PMC2789288, DOI: 10.1213/ane.0b013e3181b81068.Peer-Reviewed Original ResearchMeSH KeywordsAprotininBlood CoagulationBlood Coagulation TestsBlood PlateletsCoronary Artery Bypass, Off-PumpDouble-Blind MethodErythrocyte TransfusionFibrinolytic AgentsGraft Occlusion, VascularHumansPeptide FragmentsPlatelet AdhesivenessPlatelet AggregationPlatelet Function TestsPostoperative HemorrhageProspective StudiesProthrombinReceptor, PAR-1ThrombinThrombosisTreatment OutcomeWound HealingConceptsMajor adverse cardiovascular eventsProtease-activated receptor 1Adverse cardiovascular eventsSaphenous vein graftsCardiovascular eventsOPCAB surgeryAprotinin groupCoronary sinusHypercoagulable stateVein graftsThrombin generationAntifibrinolytic propertiesPump coronary artery bypass surgeryOff-pump coronary surgeryCoronary artery bypass surgeryRed blood cell transfusionAprotinin-treated patientsFull-dose regimenArtery bypass surgeryBlood cell transfusionCoronary sinus bloodPAR-1 antagonistsPlatelet-leukocyte conjugatesPAR-1 activationPlatelet-derived microparticlesThrombin and interleukin-1β decrease HOX gene expression in human first trimester decidual cells: implications for pregnancy loss
Sarno J, Schatz F, Huang SJ, Lockwood C, Taylor HS. Thrombin and interleukin-1β decrease HOX gene expression in human first trimester decidual cells: implications for pregnancy loss. Molecular Human Reproduction 2009, 15: 451-457. PMID: 19389728, PMCID: PMC2722817, DOI: 10.1093/molehr/gap030.Peer-Reviewed Original ResearchConceptsFirst trimester decidual cellsSpontaneous pregnancy lossPregnancy lossIL-1beta treatmentIL-1betaDecidual cellsMedroxyprogesterone acetateHuman first trimester decidual cellsFirst trimester deciduaProduction of cytokinesThrombin treatmentReal-time RT-PCRPregnancy outcomesSurgical treatmentViable pregnancyEarly pregnancySuccessful pregnancyElective terminationTrimester deciduaDefective implantationInflammation resultsInterleukin-1betaReal-time PCRThrombin generationAffymetrix microarray analysis
2008
Acute Onset Human Atrial Fibrillation Is Associated With Local Cardiac Platelet Activation and Endothelial Dysfunction
Akar JG, Jeske W, Wilber DJ. Acute Onset Human Atrial Fibrillation Is Associated With Local Cardiac Platelet Activation and Endothelial Dysfunction. Journal Of The American College Of Cardiology 2008, 51: 1790-1793. PMID: 18452786, DOI: 10.1016/j.jacc.2007.11.083.Peer-Reviewed Original ResearchConceptsAcute onset atrial fibrillationSystemic platelet activationRisk factorsPlatelet activationHypercoagulable stateAtrial fibrillationAF groupThrombin generationBlood samplesControl groupUnderwent radiofrequency catheter ablationPlatelet P-selectin expressionOnset atrial fibrillationBaseline blood samplesRadiofrequency catheter ablationMinutes of onsetBeats/minP-selectin expressionBurst atrial pacingHuman atrial fibrillationNitric oxide productionEnzyme-linked immunosorbentLocal thrombin generationInflammatory markersProthrombotic state
2006
Antithrombin reduces monocyte and neutrophil CD11b up regulation in addition to blocking platelet activation during extracorporeal circulation
Rinder CS, Rinder HM, Smith MJ, Fitch JC, Tracey JB, Chandler WL, Rollins SA, Smith BR. Antithrombin reduces monocyte and neutrophil CD11b up regulation in addition to blocking platelet activation during extracorporeal circulation. Transfusion 2006, 46: 1130-1137. PMID: 16836559, DOI: 10.1111/j.1537-2995.2006.00861.x.Peer-Reviewed Original ResearchConceptsNeutrophil elastase releaseAnti-inflammatory activityAntithrombin IIICardiopulmonary bypassElastase releasePlatelet activationWhite blood cell activationDirect anti-inflammatory activitySystemic inflammatory reactionAbsence of endotheliumEndothelial effectsCardiac surgeryBlood cell activationAnticoagulant effectExtracorporeal circulationInflammatory reactionThrombin generationHigh doseClinical relevanceCell activationFibrin generationComplement activationThrombin activityStudy designCD11b
1998
Ancylostoma caninum Anticoagulant Peptide Blocks Metastasis In Vivo and Inhibits Factor Xa Binding to Melanoma Cells In Vitro
Donnelly K, Bromberg M, Milstone A, Madison McNiff J, Terwilliger G, Konigsberg W, Cappello M. Ancylostoma caninum Anticoagulant Peptide Blocks Metastasis In Vivo and Inhibits Factor Xa Binding to Melanoma Cells In Vitro. Thrombosis And Haemostasis 1998, 79: 1041-1047. PMID: 9609244, DOI: 10.1055/s-0037-1615117.Peer-Reviewed Original ResearchConceptsAnti-metastatic activityThrombin generationAntimetastatic effectFactor XaEffector cell protease receptor-1Melanoma cellsTissue factor pathway inhibitorDose-dependent reductionFactor pathway inhibitorHuman coagulation factor XaHuman melanoma cellsFactor V/VaPulmonary metastasesSubcutaneous injectionSCID miceCoagulation factor XaVein injectionBlock metastasisReceptor 1Inhibits factor XaPathway inhibitorTumor cellsXa concentrationsProthrombinase activityPotential mechanisms
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply